{"id":"W1803778850","doi":"10.1002/ana.24339","title":"Switch to natalizumab versus fingolimod in active relapsing–remitting multiple sclerosis","year":2014,"lang":"en","type":"article","venue":"Annals of Neurology","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":159,"is_retracted":false,"has_abstract":true,"ca_institutions":"Hôpital Charles-Le Moyne; Hôpital Notre-Dame; Cégep de Lévis","funders":"National Health and Medical Research Council; EMD Serono; Canadian Institutes of Health Research; Multiple Sclerosis Australia; Teva Pharmaceutical Industries; Novartis Pharma; Multiple Sclerosis Society; Biogen; Sanofi","keywords":"Fingolimod; Natalizumab; Medicine; Multiple sclerosis; Glatiramer acetate; Internal medicine; Propensity score matching; Hazard ratio; Cohort; Expanded Disability Status Scale; Randomized controlled trial; Physical therapy; Confidence interval; Immunology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001701126,0.0002365599,0.0007068218,0.0003051772,0.0002641681,0.0006000355,0.000349321,0.000521104,0.001897037],"category_scores_gemma":[0.003047602,0.000156183,0.0007695669,0.0003635159,0.000210835,0.0004112606,0.0003415075,0.0005495368,0.0002273512],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004566192,"about_ca_system_score_gemma":0.0003008188,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008126175,"about_ca_topic_score_gemma":0.001085204,"domain_scores_codex":[0.9991461,0.0003763114,0.00008727239,0.0001829101,0.0001174795,0.00008989694],"domain_scores_gemma":[0.9989895,0.0003993079,0.000370796,0.00007583301,0.0000330716,0.0001314084],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.5558079,0.005562076,0.2913902,0.0005998318,0.005150856,0.0005283903,0.0005041891,0.001352272,0.005562697,0.0001835449,0.001479665,0.1318783],"study_design_scores_gemma":[0.04881922,0.06631844,0.8674567,0.000251756,0.004925596,0.0009759975,0.0004167762,0.003580691,0.003023834,0.000683972,0.00350409,0.00004294713],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9986178,0.0009229803,0.00005873773,0.00006311478,0.00002655667,0.00002871554,0.00009109893,0.00000471977,0.0001863211],"genre_scores_gemma":[0.9990088,0.0003886652,0.00007987313,0.000100719,0.00003092931,0.00003336242,0.0002433519,0.000001544445,0.0001127656],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001897037,"threshold_uncertainty_score":0.008996546,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2028620345828532,"score_gpt":0.3749256953309814,"score_spread":0.1720636607481283,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}